Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Por um escritor misterioso
Descrição
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks, Journal of Hematology & Oncology
Frontiers Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study - eClinicalMedicine
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Frontiers Will Host Genetics Affect the Response to SARS-CoV-2 Vaccines? Historical Precedents
Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases, Inflammation and Regeneration
COVID-19 vaccines and a perspective on Africa: Trends in Immunology
Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study - The Lancet Healthy Longevity
de
por adulto (o preço varia de acordo com o tamanho do grupo)
